| Code | CSB-RA624104MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to secukinumab, targeting human interleukin-17A (IL-17A), a pro-inflammatory cytokine central to immune-mediated pathological processes. IL-17A is primarily produced by Th17 cells and plays a crucial role in host defense against extracellular pathogens, but its dysregulation contributes to chronic inflammatory and autoimmune conditions. Elevated IL-17A levels are implicated in psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory disorders, where it promotes neutrophil recruitment, keratinocyte proliferation, and tissue inflammation through induction of inflammatory mediators.
Secukinumab is a fully humanized IgG1 monoclonal antibody that selectively binds and neutralizes IL-17A, preventing its interaction with the IL-17 receptor. This biosimilar antibody provides researchers with a valuable tool for investigating IL-17A-mediated signaling pathways, studying the immunopathogenesis of autoimmune diseases, and evaluating therapeutic mechanisms in preclinical models. It supports applications in immunology research, cytokine biology studies, and the development of targeted anti-inflammatory strategies.
There are currently no reviews for this product.